JP2016503030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503030A5 JP2016503030A5 JP2015548025A JP2015548025A JP2016503030A5 JP 2016503030 A5 JP2016503030 A5 JP 2016503030A5 JP 2015548025 A JP2015548025 A JP 2015548025A JP 2015548025 A JP2015548025 A JP 2015548025A JP 2016503030 A5 JP2016503030 A5 JP 2016503030A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- composition according
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 77
- 150000001875 compounds Chemical class 0.000 claims description 68
- 239000004094 surface-active agent Substances 0.000 claims description 43
- 239000011859 microparticle Substances 0.000 claims description 40
- 208000031886 HIV Infections Diseases 0.000 claims description 20
- 208000037357 HIV infectious disease Diseases 0.000 claims description 20
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000003381 stabilizer Substances 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000000337 buffer salt Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 4
- DSNLMYRCHYFVDO-UHFFFAOYSA-N [5a,5b,8,8,11a-pentamethyl-9-(oxan-2-yloxy)-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-3a-yl]methyl 4-methylbenzenesulfonate Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4OCCCC4)CCC3(C)C2CC2)C)(C)C2C2C(C(=C)C)CCC21COS(=O)(=O)C1=CC=C(C)C=C1 DSNLMYRCHYFVDO-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims description 4
- 229960002814 rilpivirine Drugs 0.000 claims description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 4
- 229960000311 ritonavir Drugs 0.000 claims description 4
- -1 fatty acid esters Chemical class 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229940124522 antiretrovirals Drugs 0.000 claims description 2
- 239000003903 antiretrovirus agent Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 8
- 241000282412 Homo Species 0.000 claims 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737177P | 2012-12-14 | 2012-12-14 | |
| US61/737,177 | 2012-12-14 | ||
| PCT/US2013/075196 WO2014093941A1 (en) | 2012-12-14 | 2013-12-14 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503030A JP2016503030A (ja) | 2016-02-01 |
| JP2016503030A5 true JP2016503030A5 (OSRAM) | 2017-02-02 |
Family
ID=50935020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548025A Pending JP2016503030A (ja) | 2012-12-14 | 2013-12-14 | 医薬組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9795619B2 (OSRAM) |
| EP (1) | EP2931285A4 (OSRAM) |
| JP (1) | JP2016503030A (OSRAM) |
| KR (1) | KR20150093819A (OSRAM) |
| CN (1) | CN104902905A (OSRAM) |
| AU (1) | AU2013358897B2 (OSRAM) |
| BR (1) | BR112015013695A2 (OSRAM) |
| CA (1) | CA2893959A1 (OSRAM) |
| CL (1) | CL2015001660A1 (OSRAM) |
| CR (1) | CR20150313A (OSRAM) |
| EA (1) | EA201590862A1 (OSRAM) |
| HK (1) | HK1209638A1 (OSRAM) |
| IL (1) | IL238807A0 (OSRAM) |
| MA (1) | MA38182A1 (OSRAM) |
| MX (1) | MX2015007563A (OSRAM) |
| PE (1) | PE20151326A1 (OSRAM) |
| PH (1) | PH12015501156A1 (OSRAM) |
| SG (2) | SG11201503807TA (OSRAM) |
| WO (1) | WO2014093941A1 (OSRAM) |
| ZA (1) | ZA201503594B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| KR20150093819A (ko) * | 2012-12-14 | 2015-08-18 | 글락소스미스클라인 엘엘씨 | 약제 조성물 |
| AU2013361401C1 (en) | 2012-12-21 | 2018-08-09 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| WO2014105926A1 (en) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Novel betulinic acid proline derivatives as hiv inhibitors |
| PL3019503T3 (pl) | 2013-07-12 | 2018-01-31 | Gilead Sciences Inc | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| NO2865735T3 (OSRAM) | 2013-07-12 | 2018-07-21 | ||
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (OSRAM) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| US20170129916A1 (en) | 2014-06-26 | 2017-05-11 | Hetero Research Foundation | Novel betulinic proline imidazole derivatives as hiv inhibitors |
| MX2017003928A (es) * | 2014-09-26 | 2017-06-28 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmaceuticas de accion prolongada. |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| WO2016147099A2 (en) | 2015-03-16 | 2016-09-22 | Hetero Research Foundation | C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors |
| CN110790773A (zh) | 2015-04-02 | 2020-02-14 | 吉利德科学公司 | 多环氨甲酰基吡啶酮化合物及其药物用途 |
| WO2018042332A1 (en) * | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018042331A1 (en) * | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| KR20200031658A (ko) | 2017-07-21 | 2020-03-24 | 비이브 헬쓰케어 컴퍼니 | Hib 감염 및 aids를 치료하기 위한 요법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5358721A (en) * | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
| WO2001090046A1 (en) | 2000-05-23 | 2001-11-29 | Univerzita Palackeho V Olomouci | Triterpenoid derivatives |
| WO2003011254A1 (en) * | 2001-07-31 | 2003-02-13 | Capricorn Pharma Inc. | Amorphous drug beads |
| US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
| US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| WO2005112929A2 (en) * | 2004-05-20 | 2005-12-01 | Cornell Research Foundation, Inc. | Anti-hiv-1 activity of betulinol derivatives |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| CN1682740A (zh) * | 2005-03-11 | 2005-10-19 | 中国药科大学 | 五环三萜类化合物在制备糖原磷酸化酶抑制剂中的应用 |
| US20090023698A1 (en) | 2005-03-29 | 2009-01-22 | Krasutsky Pavel A | Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid |
| TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Ｈｉｖ-感染之預防 |
| WO2006117666A2 (en) * | 2005-04-29 | 2006-11-09 | Pfizer Inc. | Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery |
| EP1986654A2 (en) | 2006-02-21 | 2008-11-05 | Achillion Pharmaceuticals, Inc. | Substituted taraxastanes useful for treating viral infections |
| FI121468B (fi) * | 2006-06-07 | 2010-11-30 | Valtion Teknillinen | Betuliiniperäiset yhdisteet antimikrobisina aineina |
| SG173315A1 (en) | 2006-06-23 | 2011-08-29 | Tibotec Pharm Ltd | Aqueous suspensions of tmc278 |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| AR063546A1 (es) * | 2006-11-03 | 2009-01-28 | Panacos Pharmaceuticals Inc | DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH. |
| SI2175857T1 (sl) * | 2007-07-12 | 2014-01-31 | Janssen R&D Ireland | Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila |
| CN101981047A (zh) | 2008-01-03 | 2011-02-23 | Viro化学制药公司 | 新的羽扇烷衍生物 |
| JP2011508747A (ja) * | 2008-01-03 | 2011-03-17 | バイロケム ファーマ インコーポレイテッド | 新規のｃ−２１ケトルパン誘導体、それらの調製および使用 |
| DE102008037025C5 (de) * | 2008-08-08 | 2016-07-07 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| CZ301318B6 (cs) | 2008-11-13 | 2010-01-13 | Univerzita Palackého v Olomouci | 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo |
| CA2744019C (en) * | 2008-12-11 | 2017-03-14 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| US8802727B2 (en) | 2009-07-14 | 2014-08-12 | Hetero Research Foundation, Hetero Drugs Limited | Pharmaceutically acceptable salts of betulinic acid derivatives |
| BR112012019762A2 (pt) * | 2010-02-11 | 2016-02-23 | Glaxosmithkline Llc | composto, composição, e, método para tratar uma doença. |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| WO2013020245A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Carbonyl derivatives of betulin |
| WO2013020246A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Methylene derivatives of betulin |
| EP2791102B1 (en) | 2011-12-14 | 2016-05-18 | Glaxosmithkline LLC | Propenoate derivatives of betulin |
| JO3387B1 (ar) * | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| US20150209273A1 (en) | 2012-08-28 | 2015-07-30 | Glaxosmithkline Llc | Pharmaceutical Compositions |
| KR20150093819A (ko) * | 2012-12-14 | 2015-08-18 | 글락소스미스클라인 엘엘씨 | 약제 조성물 |
| MX2017003928A (es) | 2014-09-26 | 2017-06-28 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmaceuticas de accion prolongada. |
-
2013
- 2013-12-14 KR KR1020157018488A patent/KR20150093819A/ko not_active Withdrawn
- 2013-12-14 EA EA201590862A patent/EA201590862A1/ru unknown
- 2013-12-14 SG SG11201503807TA patent/SG11201503807TA/en unknown
- 2013-12-14 BR BR112015013695A patent/BR112015013695A2/pt not_active IP Right Cessation
- 2013-12-14 SG SG10201704467SA patent/SG10201704467SA/en unknown
- 2013-12-14 CA CA2893959A patent/CA2893959A1/en not_active Abandoned
- 2013-12-14 HK HK15110448.0A patent/HK1209638A1/xx unknown
- 2013-12-14 US US14/651,673 patent/US9795619B2/en not_active Expired - Fee Related
- 2013-12-14 AU AU2013358897A patent/AU2013358897B2/en not_active Ceased
- 2013-12-14 WO PCT/US2013/075196 patent/WO2014093941A1/en not_active Ceased
- 2013-12-14 MA MA38182A patent/MA38182A1/fr unknown
- 2013-12-14 CN CN201380065306.9A patent/CN104902905A/zh active Pending
- 2013-12-14 PE PE2015000924A patent/PE20151326A1/es not_active Application Discontinuation
- 2013-12-14 JP JP2015548025A patent/JP2016503030A/ja active Pending
- 2013-12-14 MX MX2015007563A patent/MX2015007563A/es unknown
- 2013-12-14 EP EP13863026.4A patent/EP2931285A4/en not_active Withdrawn
-
2015
- 2015-05-13 IL IL238807A patent/IL238807A0/en unknown
- 2015-05-21 ZA ZA2015/03594A patent/ZA201503594B/en unknown
- 2015-05-25 PH PH12015501156A patent/PH12015501156A1/en unknown
- 2015-06-12 CL CL2015001660A patent/CL2015001660A1/es unknown
- 2015-06-12 CR CR20150313A patent/CR20150313A/es unknown
-
2017
- 2017-10-19 US US15/787,987 patent/US20180042944A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503030A5 (OSRAM) | ||
| JP2017528497A5 (OSRAM) | ||
| JP6231385B2 (ja) | 医薬組成物 | |
| FI2346495T4 (fi) | Farmaseuttinen formulaatio 514 | |
| AU2020263285B2 (en) | Continuous delivery of lenalidomide and other immunomodulatory agents | |
| US10092523B2 (en) | Long acting pharmaceutical compositions | |
| EP2931285A1 (en) | Pharmaceutical compositions | |
| KR102794804B1 (ko) | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 | |
| FI3541366T3 (fi) | Exendiinin (9-39) puskuroidut formulaatiot | |
| NZ711179A (en) | Oral formulations of deferasirox | |
| KR20230116837A (ko) | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 | |
| KR20230116836A (ko) | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 | |
| TW202237145A (zh) | 莫奈皮拉韋的醫藥組成物 | |
| JP2015504094A5 (OSRAM) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| JP2019532939A5 (OSRAM) | ||
| JP2019509309A5 (OSRAM) | ||
| JP2016514706A5 (OSRAM) | ||
| RU2021102950A (ru) | Твердые фармацевтические композиции для лечения вируса гепатита с | |
| CN102573815B (zh) | Hiv感染的治疗和预防 | |
| HK40060778A (en) | Continuous delivery of lenalidomide and other immunomodulatory agents | |
| García et al. | Systemic Antimicrobials: Antibiotics, Antifungals, Antivirals, Antiparasitics | |
| CN104000795A (zh) | 一种甘草酸二铵控释片及其制备方法 |